Publications Repository

Publications Repository

View item 
  •   Home
  • ICR Divisions
  • Clinical Studies
  • View item
  • Home
  • ICR Divisions
  • Clinical Studies
  • View item
JavaScript is disabled for your browser. Some features of this site may not work without it.

Nintedanib plus docetaxel as second-line therapy in patients with non-small-cell lung cancer of adenocarcinoma histology: a network meta-analysis vs new therapeutic options.

Thumbnail
View/Open
Supporting information (63.31Kb)
Date
2017-06
ICR Author
Popat, Sanjay
Marsden,
Author
Popat, S
Mellemgaard, A
Reck, M
Hastedt, C
Griebsch, I
Type
Journal Article
Metadata
Show full item record
Abstract
Patients & methods We provide an update to a network meta-analysis evaluating the relative efficacy of nintedanib + docetaxel versus other second-line agents in adenocarcinoma histology non-small-cell lung cancer.Results Overall similarity of nintedanib + docetaxel versus ramucirumab + docetaxel, and versus nivolumab. Comparing nintedanib + docetaxel with nivolumab, hazards ratio (HR) of overall survival and progression-free survival (PFS) pointed in opposite directions (overall survival: HR: 1.20 [95% credible interval: 0.92-1.58]; PFS: HR: 0.91 [0.68-1.21]). Exploratory subgroup analysis indicated superiority of nivolumab in high PD-L1 expression level subgroups; results were more favorable for nintedanib in all subgroups with low (<1%, <5%, <10%) PD-L1 expression levels - in particular, with regard to PFS.Conclusion Results demonstrated similar efficacy of nintedanib + docetaxel compared with the new therapeutic options ramucirumab + docetaxel and nivolumab, with potential differences in subgroups according to PD-L1 expression level.
URI
https://repository.icr.ac.uk/handle/internal/1311
DOI
https://doi.org/10.2217/fon-2016-0493
Collections
  • Clinical Studies
Subject
Humans
Adenocarcinoma
Carcinoma, Non-Small-Cell Lung
Taxoids
Indoles
Antineoplastic Combined Chemotherapy Protocols
Antibodies, Monoclonal
Disease-Free Survival
Treatment Outcome
Gene Expression Regulation, Neoplastic
Antibodies, Monoclonal, Humanized
Network Meta-Analysis
B7-H1 Antigen
Docetaxel
Nivolumab
Research team
Thoracic Oncology
Language
eng
License start date
2017-06
Citation
Future oncology (London, England), 2017, 13 (13), pp. 1159 - 1171

Browse

All of ICR repositoryICR DivisionsBy issue dateAuthorsTitlesPublication TypesThis collectionBy issue dateAuthorsTitlesPublication Types
  • Login
  • Registered office: The Institute of Cancer Research, 123 Old Brompton Road, London, SW7 3RP
    A Charity, Not for Profit. Company Limited by Guarantee.
    Registered in England No. 534147. VAT Registration No. GB 849 0581 02.